Nature Communications (Dec 2017)
EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer
- Barbara Oldrini,
- Wan-Ying Hsieh,
- Hediye Erdjument-Bromage,
- Paolo Codega,
- Maria Stella Carro,
- Alvaro Curiel-García,
- Carl Campos,
- Maryam Pourmaleki,
- Christian Grommes,
- Igor Vivanco,
- Daniel Rohle,
- Craig M. Bielski,
- Barry S. Taylor,
- Travis J. Hollmann,
- Marc Rosenblum,
- Paul Tempst,
- John Blenis,
- Massimo Squatrito,
- Ingo K. Mellinghoff
Affiliations
- Barbara Oldrini
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
- Wan-Ying Hsieh
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
- Hediye Erdjument-Bromage
- Molecular Biology Program, Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center
- Paolo Codega
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
- Maria Stella Carro
- Department of Neurosurgery, University of Freiburg
- Alvaro Curiel-García
- Seve Ballesteros Foundation Brain Tumor Group, Spanish National Cancer Research Centre
- Carl Campos
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
- Maryam Pourmaleki
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
- Christian Grommes
- Department of Neurology, Memorial Sloan Kettering Cancer Center
- Igor Vivanco
- Division of Cancer Therapeutics, The Institute of Cancer Research
- Daniel Rohle
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
- Craig M. Bielski
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center
- Barry S. Taylor
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
- Travis J. Hollmann
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Marc Rosenblum
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Paul Tempst
- Molecular Biology Program, Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center
- John Blenis
- Department of Pharmacology, Weill Cornell Graduate School of Medical Sciences
- Massimo Squatrito
- Seve Ballesteros Foundation Brain Tumor Group, Spanish National Cancer Research Centre
- Ingo K. Mellinghoff
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
- DOI
- https://doi.org/10.1038/s41467-017-02185-w
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 12
Abstract
The epidermal growth factor receptor (EGFR) signalling is regulated at multiple levels. Here the authors show that the importin RanBP6 acts as a tumor suppressor in Glioblastoma and regulates EGFR signalling through promoting translocation of STAT3 to the nuclei and repressing EGFR transcription.
